Enzymatica AB: Excellent volume growth for ColdZyme®

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Enzymatica AB: Excellent volume growth for ColdZyme®

Q2             

  • Net sales reached SEK 4.9 (3.1) million.
  • Loss after tax came in at SEK -12.3 (-10.4) thousand.
  • Earnings per share were SEK -0.20 (-0.42).
  • Cash and cash equivalents were SEK 26.9 (23.4) thousand

Significant events in Q2

  • Enzymatica completed its acquisition of Icelandic company Zymetech effective April 1.
  • Enzymatica completed its new share issue, raising SEK 60 million before issue expenses.

H1                      

  • Net sales increased to SEK 13.3 (10.0) million.
  • Loss after tax came in at SEK -20.9 (-19.5) million.
  • Earnings per share were SEK -0.47 (-0.78).
Financial ratios             
(SEK THOUSAND) Q2 2016 Q2 2015 H1 2016 H1 2015 Full year 2015
Net sales 4.9 3.1 13.3 10.0 27.9
Gross margin, % 63 86 62 76 70
Operating profit/loss -12.3 -10.4 -20.0 -19.5 -40.5
Cash flow from operating activities -15.1 -7.9 -19.9   -12.7 -37.7
Average number of employees 22 15 19 15 16

(Zymetech is consolidated in Enzymatica's figures as at April 1, 2016)

CEO statement: With the Zymetech acquisition, we are entering a new phase

We started off the quarter by completing the acquisition of Icelandic company Zymetech, and a new share issue in the amount of SEK 60 million was conducted in May. Enzymatica's stated objective is to establish international sales via renowned partners, and now we are in the process of putting in place the final pieces of a stable foundation. The acquisition of Zymetech gave us a patent family with high strategic significance and know-how relating to the enzyme technology on which ColdZyme is based. We can thus now offer our potential distribution partners both exclusivity and high-class collaboration. Given that Enzymatica and the success of ColdZyme in Sweden are still relatively unknown on the global market, we need to be patient and realize the fact that the internationalization process will take time. This makes it all the more gratifying that we are continuing to increase sales on the markets on which we already operate. Sales in H1 (including Zymetech) were up 32% year-on-year, and increased by 58% in Q2. The number of ColdZyme units sold to end consumers from Swedish pharmacies increased in Q2 by 37%, which indicates a continuing increase in customer demand. As previously announced, it is now important to pitch the success of ColdZyme on the domestic market to potential distribution partners outside of the Nordic region. We are primarily concentrating on the European market, because the product is already CE-marked in the EU. We have also established contacts outside of Europe in parallel because the time for approval processes in other parts of the world prolongs the time to launch.

Meanwhile, the Zymetech integration process is proceeding according to plan. Enzymatica is making a minor investment in the production plant in Iceland in 2016 to secure access to the enzyme and raise production capacity for future expansion.

We are now in the off season for colds, but I'm confidently looking forward to the second half of the year and to our sales continuing to increase. By the end of the year, we should be able to see the first results of our efforts to sign contracts with new distributors, and we also expect at that time to be able to present the results of our ongoing follow-up study of ColdZyme, which is currently in progress in the UK.  

Fredrik Lindberg, CEO

Enzymatica at a glance Enzymatica AB is a life science company whose business concept is to develop medical devices based on barrier technology and marine enzymes for self care in major market segments. In a short period of time, the company developed ColdZyme®, a unique mouth spray for fighting colds, launched the product in six markets and reached a position over the past winter as one of the most-sold cold products in Swedish pharmacies measured in SEK. Enzymatica has its own sales organization in Scandinavia and collaborates with a contract sales organization in the UK. Enzymatica also sells via distributers in Finland and Spain.

Our development focuses on medical devices for upper respiratory tract infections and oral health. An enzyme from deep-sea fish is a key sub-component in product development.

Enzymatica was founded in 2007, has its head office in Lund, Sweden and has been listed on the Nasdaq First North since June 15, 2015.

For questions about this report, please contact: Fredrik Lindberg, CEO, Enzymatica AB Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com

Bengt Jöndell, Interim CFO, Enzymatica AB Tel: +46 (0)703-77 71 70  | Email: bengt.jondell@enzymatica.com

HUG#2028961

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 181

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 122

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 203

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 233

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 182

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Notice: Humacyte Investors Should Act Now

Updated Category News Views 117

Understanding the Investigation into Humacyte Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is actively looking into potential claims related to Humacyte, Inc. (NASDAQ: HUMA). This investigation comes as a significant opportunity for investors who may have suffered losses exceeding $75,000 during certain periods of the...

Continue Reading
Marco's Pizza Partners with Karate Kid: Legends for Film Launch

Updated Category News Views 206

Marco's Pizza and Karate Kid: Legends Collaboration In an exciting move to engage fans, Marco's Pizza, one of the fastest-growing pizza franchises, has teamed up with Sony Pictures' Karate Kid: Legends. This collaboration aims to celebrate the cherished Karate Kid series with a mouthwatering promotion that promises to delight both pizza and movie enthusiasts. Delicious...

Continue Reading
Innovative Tactile Makeup Palette Supports Vision Impaired Users

Updated Category News Views 352

Introduction to an Inclusive Beauty Initiative Makeup has long been synonymous with beauty and self-expression, yet it has often excluded a significant segment of the population: those who are blind or have low vision. Recognizing this critical gap, the Shine Foundation has collaborated with Cheekbone Beauty to create a groundbreaking solution in the beauty...

Continue Reading
Carver Bancorp Appoints Donald Felix as New Leader

Updated Category News Views 196

Carver Bancorp Welcomes Donald Felix as President and CEO Carver Bancorp, Inc. has made a significant announcement: Donald Felix is now its President and CEO. This marks an important chapter for Carver, which is well-known for its dedication to supporting underserved communities. A Legacy of Service and Community Investment Established in 1948, Carver has consistently led...

Continue Reading
Navigating Merger Concerns with SpartanNash Company Insights

Updated Category News Views 258

Understanding the SpartanNash Merger Situation As the merger of SpartanNash Company (NASDAQ: SPTN) with C&S Wholesale Grocers unfolds, there’s considerable interest in the deal, which proposes a cash buyout of $26.90 per share for SpartanNash shareholders. This sort of transaction can be complex, and it prompts many to wonder whether the offer truly represents a fair...

Continue Reading